Clinical observation on the efficacy of CyberKnife for primary or metastatic retroperitoneal tumours

Zhuang, Hong; Song, Yong; Wang, J.; Zhao, Lujun; Wang, Ping

doi:10.1111/ecc.12112

Cited by 3 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The methodology used for CyberKnife SRT and treatment planning has been described in detail in our previous reports [ 21 - 23 ]. Briefly, patients were immobilized using a vacuum bag before CT simulation.…”

Section: Methodsmentioning

confidence: 99%

Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

AimsTo evaluate the safety and efficacy of stereotactic radiotherapy (SRT, both stereotactic body RT [SBRT] and fractionated stereotactic RT [FSRT]) in the treatment of patients with recurrent or second primary mediastinal lymph node metastases (R/SP-MLNMs) originating from non-small cell lung cancer (NSCLC).MethodsBetween 10/2006 and 7/2013, patients with R/SP-MLNMsoriginating from NSCLC were enrolled and treated with SRT at our hospital; their data was stored in prospectively-collected database. The enrolled patients were divided into Group A (without prior RT) and Group B (with prior RT). The primary end-point was overall survival (OS). The secondary end-points were the MLNM local control (LC), the time to symptom alleviation, and toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0).ResultsThirty-three patients were treated (16 in Group A with 19 R/SP-MLNMs and 17 in Group B with 17 R/SP-MLNMs). For the entire cohort, the median OS was 25.5 months with a median follow-up of 20.9 months (range, 3.2-82). The 1-year and 3-year actuarial LC rates were 100% and 86%, respectively. Symptom alleviation was observed in 52% of patients, after a median of 6 days (range, 3-18). CTCAE v4.0 ≥ Grade 3 toxicities occurred in 5 patients (15%; all in Group B); among them, Grade 5 in 2 patients.ConclusionsWe recommend exercising extreme caution in using SRT for R/SP-MLNMs in patients who received prior RT (particularly to LN station 7). For patients without previous RT, SRT appears to be safe and efficacious treatment modality; prospective studies are warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The methodology used for CyberKnife SRT and treatment planning has been described in detail in our previous reports [21][22][23]. Briefly, patients were immobilized using a vacuum bag before CT simulation.…”

Section: Treatment Schedulementioning

confidence: 99%

Clinical Evaluation Stereotactic Radiation Therapy for Recurrent or Second Primary Mediastinal Lymph Node Metastases Originating From Non-Small Cell Lung Cancer

Mao

Wang

Zaorsky

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are few studies reported in the literature evaluating the response to guided radiotherapy with the CyberKnife system in patients with retroperitoneal tumors. A study by Zhuang H et al,23 reported a complete response and stability of the disease in 48% and 18% of the cases,…”

mentioning

confidence: 97%

“…23 . There are few studies reported in the literature evaluating the response to guided radiotherapy with the CyberKnife system in patients with retroperitoneal tumors.…”

mentioning

confidence: 99%

Tumoral reduction in patients with intra-abdominal tumors treated with CyberKnife: a single center's experience

Mora-Tous

Rodríguez-Márquez

Massaro-Ceballos

et al. 2022

revsal

View full text Add to dashboard Cite

Introduction: to estimate tumoral reduction and overall survival at one year in a series of patients with abdominal tumors treated with body fractionated stereotactic radiotherapy (SBRT). Methods: retrospective descriptive study of a series of patients with abdominal tumors (solid or hollow viscus), treated with image-guided SBRT using a CyberKnife system and who had post-treatment follow-up and control images. The study was completed at the XXXXXXX in a five-year period from January 2013 to January 2018, in XXXXXXX. Results: 16 patients were included. 75% of the cases were under 65 years of age. The treated lesions were located in the pancreas (37.5%), abdomino-pelvic lymph nodes (25%), liver (25%) and retroperitoneum (12.5%). Most of the treated patients required up to two fiduciary markers (93.7%). The SBRT dose applied ranged from 24 to 60 Gy, mostly in 3 fractions (81.3%). Mean tumoral reduction after treatment was of 15.6 mm (SD ±13.5), being statistically significant (p <0.0003). According to RECIST 1.1 criteria, a complete response was achieved in 6.2% (n=1) of the cases, a partial response in 56.3% (n=9), and stable disease in 37.5% (n=6). No disease progression was documented in any patient during the follow-up period. The one-year overall survival rate was 93.7%. Conclusion: experience at this center shows that Cyberknife radiosurgery in both primary and metastatic abdominal tumors provides, in the short term, an adequate local control rate and improved one-year overall survival.

show abstract

Clinical observation on the efficacy of CyberKnife for primary or metastatic retroperitoneal tumours

Cited by 3 publications

References 21 publications

Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer

Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer

Clinical Evaluation Stereotactic Radiation Therapy for Recurrent or Second Primary Mediastinal Lymph Node Metastases Originating From Non-Small Cell Lung Cancer

Tumoral reduction in patients with intra-abdominal tumors treated with CyberKnife: a single center's experience

Contact Info

Product

Resources

About